The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treatment option for advanced HCC due to their superior...
Main Authors: | Landon L. Chan, Stephen L. Chan |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of the Liver
2023-10-01
|
Series: | Clinical and Molecular Hepatology |
Subjects: | |
Online Access: | http://e-cmh.org/upload/pdf/cmh-2023-0114.pdf |
Similar Items
-
The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
by: Matthew Man Pok Lee, et al.
Published: (2023-09-01) -
The prime time for management of hepatocellular carcinoma in Hong Kong
by: Landon L. Chan, et al.
Published: (2023-04-01) -
Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma
by: Landon L. Chan, et al.
Published: (2022-03-01) -
The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
by: Patrizia Leone, et al.
Published: (2021-05-01) -
Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
by: Hsueh-Chien Chiang, et al.
Published: (2023-01-01)